Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model
about
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsEffects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMCReplication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Immunomodulation of cancer: potential use of selectively replicating agents.EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelRequirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis.Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunityEmerging strategies for EphA2 receptor targeting for cancer therapeutics.Immune therapy for breast cancer in 2010-hype or hope?Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancerAdenoviral vectors: development and application.Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLTCombinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancerCXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells.Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral productsAdenoviral vector-based strategies for cancer therapy.Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease.Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cellsImmunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma.Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo.Gene therapy strategies for carcinoma of the breast.The promise and reality of cancer gene therapy.HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.
P2860
Q24631515-4722891B-1DC6-42D9-ACC8-26475FD87F10Q24793078-69A75BC5-B927-4885-9B56-C12D588B6382Q28559652-65259ECD-F36B-4E33-9C12-08F1279A2883Q33811204-2DE17A26-7792-49FE-96D9-3B0183B4DAD9Q33904276-16FDE27D-E1AF-4895-82C2-6B1BCA30CB5CQ33924763-6064BCE9-1814-475C-925E-8837DF58D118Q33996549-59C99070-1228-4302-B689-350305C92AE2Q34344404-F471747E-FDAD-4526-A385-9F512C34DF2AQ34469271-910AAF46-8844-4A45-9701-9A0F4B7E4E41Q34541467-1E799187-4E52-4730-A079-A410CCAB9FFFQ35201112-00590F1D-032F-4CF5-87E7-EC1A3A7C777DQ35870225-7D1770EB-FEA0-4F3E-B3E8-840C2861C4D0Q35915922-9054EC54-F1DC-4A38-B8B7-0692AD70A009Q36093425-859F82B3-EF4E-41CF-8D6F-925DE9A7385DQ36178285-77606F53-8696-43FE-9DC6-0D8496274668Q36179657-B4B8BFA3-5322-40F6-B2BE-F27FF53B11EEQ36338316-210F3994-3E60-4D32-914A-9CF9D2F6EA9CQ36422849-52D2E356-624E-4278-88A9-97E7604D0D43Q36498762-91BB9DC9-BCB0-4ADA-AA03-D44196983337Q36600110-DC48EADB-AC21-4E7E-8105-5130D68C9BD8Q36621492-A753E6A1-C5AB-41AC-8986-156667A9EBCBQ36670973-4A0DE88D-3A03-4EE5-8C84-029CA6E8FDB4Q36944172-60F443BE-1B66-41BA-A3E0-AE20A34BCEFFQ37309252-BB066D4D-327E-4387-AEC8-24EA34256A5CQ37374242-38FB8F72-3AA4-4EF0-9B08-9D0ACE9DAA0AQ37409025-24E0A040-93B5-455A-B803-DDF6CC464354Q38772887-B8CCCE89-4CCC-4BB7-8BCE-82CC695A4586Q39794841-ADF1BD20-3010-44A8-AD93-151E8AEA0B1EQ39875151-0F740CA1-50A7-4DDB-BCF9-578DC0BC6162Q40503840-CCA90D0E-0D11-43C8-8C5E-C895DD086845Q40516862-8D17092A-6901-41DF-8EB5-66BA8332D520Q40524527-A3BADA89-88D7-468C-A640-18459416B05EQ40606240-F00808A4-E782-42FA-B37C-8F3831C6E954Q40644787-6782964A-1261-480C-9CA3-69AB1C422A4AQ40674940-A97B4541-71EF-4F44-BD7C-287C8FF339A2Q40729470-C044AFE9-86D9-4F8C-8D19-FE67522C0C0DQ41100236-79E16BF3-203E-42A2-B4EB-C1423A55B556Q41540501-E6FF5783-29CE-4B4A-A68B-1832A4D3D37EQ41650537-52C1EAEA-5250-4D00-8B1A-B4C4B5926D6CQ42288961-DCD99963-63D2-4702-8617-747B97F07377
P2860
Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Intratumoral injection of an a ...... n a murine breast cancer model
@ast
Intratumoral injection of an a ...... n a murine breast cancer model
@en
type
label
Intratumoral injection of an a ...... n a murine breast cancer model
@ast
Intratumoral injection of an a ...... n a murine breast cancer model
@en
prefLabel
Intratumoral injection of an a ...... n a murine breast cancer model
@ast
Intratumoral injection of an a ...... n a murine breast cancer model
@en
P2093
P2860
P356
P1476
Intratumoral injection of an a ...... n a murine breast cancer model
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.18.8522
P407
P577
1995-08-01T00:00:00Z